All MR imaging exams were performed on a GE
Signa HDx 3.0T magnet (GE Healthcare, Waukesha, WI) using a combination of
8-channel abdominal array and
endorectal coil (Medrad, Pittsburgh, PA). The multiparametric protocol [18 (
link)] included
T1- and
T2-weighted imaging, diffusion weighted imaging (b=500,1400), and DCE MRI. DCE-MRI utilized a 3D SPGR sequence with TR/TE/α = 3.6 ms/1.3 ms/15°, FOV = 26×26 cm
2, with full gland coverage and an interpolated voxel size of 1×1×6 mm
3. Axial frames were acquired at approximately 5-second intervals to achieve a clinically appropriate compromise between spatial and temporal resolution. Gadopentetate dimeglumine (Magnevist, Berlex Laboratories, Wayne, New Jersey) was injected intravenously into an antecubital vein using a syringe pump (0.15 mmol/kg; rate 3ml/sec), followed by 20ml saline flush. The protocol included ~5 baseline scans prior to contrast injection for estimation of baseline signal intensities.
Fennessy F.M., Fedorov A., Penzkofer T., Kim K.W., Hirsch M.S., Vangel M.G., Masry P., Flood T.A., Chang M.C., Tempany C.M., Mulkern R.V, & Gupta S.N. (2015). Quantitative pharmacokinetic analysis of prostate cancer DCE-MRI at 3T: Comparison of two arterial input functions on cancer detection with digitized whole mount histopathological validation. Magnetic resonance imaging, 33(7), 886-894.